Iqvia (NYSE:IQV) Given New $200.00 Price Target at UBS Group
Iqvia (NYSE:IQV) had its price target hoisted by UBS Group from $187.00 to $200.00 in a research note published on Thursday, BenzingaRatingsTable reports. UBS Group currently has a buy rating on the medical research company’s stock.
Several other research firms also recently commented on IQV. Wells Fargo & Co initiated coverage on Iqvia in a report on Tuesday, January 7th. They issued an overweight rating and a $180.00 price objective for the company. ValuEngine downgraded Iqvia from a hold rating to a sell rating in a research note on Tuesday, February 4th. Credit Suisse Group restated a buy rating and set a $170.00 price target on shares of Iqvia in a research note on Friday, December 20th. Cfra upgraded Iqvia from a hold rating to a buy rating and boosted their price target for the company from $148.00 to $185.00 in a research note on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on Iqvia from $180.00 to $195.00 and gave the company an overweight rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $174.30.
NYSE IQV traded down $1.47 during trading hours on Thursday, hitting $164.32. The company’s stock had a trading volume of 2,962,308 shares, compared to its average volume of 1,312,776. Iqvia has a 12 month low of $130.77 and a 12 month high of $169.14. The company’s 50 day simple moving average is $158.20 and its two-hundred day simple moving average is $151.72. The company has a market cap of $31.03 billion, a P/E ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.12.
In other news, CFO Michael R. Mcdonnell sold 12,000 shares of Iqvia stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the transaction, the chief financial officer now directly owns 14,366 shares of the company’s stock, valued at approximately $2,227,735.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael J. Evanisko sold 6,250 shares of Iqvia stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $160.76, for a total value of $1,004,750.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,000 shares of company stock valued at $5,830,215. Corporate insiders own 6.00% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. First Republic Investment Management Inc. lifted its position in shares of Iqvia by 1.2% during the 4th quarter. First Republic Investment Management Inc. now owns 16,772 shares of the medical research company’s stock valued at $2,591,000 after buying an additional 200 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Iqvia during the 4th quarter valued at about $1,915,000. Ancora Advisors LLC purchased a new position in shares of Iqvia during the 4th quarter valued at about $190,000. Ellington Management Group LLC purchased a new position in shares of Iqvia during the 4th quarter valued at about $217,000. Finally, UBS Asset Management Americas Inc. lifted its position in shares of Iqvia by 7.8% during the 4th quarter. UBS Asset Management Americas Inc. now owns 749,831 shares of the medical research company’s stock valued at $115,856,000 after buying an additional 53,959 shares in the last quarter. 89.93% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: Profit Margin
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.